HERG

The main interests of the Hematological Research Group (HERG) is to identify novel risk factors for cardiovascular diseases with particular focus on venous thrombosis (VTE) , and to elucidate pathophysiological mechanism(s) involved, with special focus on the impact of genetic and environmental risk factors, and their interactions on VTE risk.

About the Group

HERG was established as a research group January 1, 2009 merged from independent research groups with common scientific focus and long-lasting collaboration. HERG is a fully integrated research group between Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø (UiT) and Section for Hematology, Division of Internal Medicine, University Hospital of North Norway (UNN). The group is formally anchored at UiT.

HERG has weekly scientific meetings for group members, and a 2-day seminaroutside the campus (UNN and UiT) in the beginning of each semester for group members and invited frontier researchers in the field to evaluate our research programme, providecutting-edge presentations, and to establish research collaborations.

Research focus

Venous thrombosis (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cardiovascular disease with an annual incidence of 1-3 per 1000 inhabitants. VTE is associated with serious short- and long-term complications, and potentially fatal outcome. In contrast to coronary artery disease (e.g. myocardial infarction), the incidence of VTE has not declined during the last decade. In many patients with life-threatening venous thrombosis, no genetic or environmental risk factors can be identified. Thus, there is an unmet need for discovery of new risk factors and expand of our knowledge on pathogenesis to advocate targeted prevention and treatment actions.

The main interests are to identify novel risk factors for cardiovascular diseases with particular focus on VTE, and to elucidate pathophysiological mechanism(s) involved in venous thrombosis, with special focus on the impact of genetic and environmental risk factors, and their interactions on VTE risk in a population-based cohort study (The Tromsø Study) (Section for Clinical Epidemiology). Experimental studies are conducted to reveal underlying mechanism(s) between exposure (risk factors) and outcome (VTE) (Section for Hemostasis and Cell Biology). Optimal clinical study design along with cutting-edge technology for genomics, cell biology, coagulation and inflammation, based on extensive regional, national, European, and transatlantic research collaboration, provide optimal conditions to deliver science of high quality within the field.

Section for haematology, including mostly residences at the Department of Hematology, is partner in a Nordic research network on malignant hematological disorders with particular focus on risk factors, pathogenesis, and treatment of Multiple Myeloma.

Main strategy

Hematological research group (HERG) aims to:

  • Be a dynamic research group consisting of highly qualified and motivated members where emphasis on common research focus should promote prosperity, security, personal growth and carrier opportunities 
  • Conduct research of high international standard through regional, national and international collaborations
  • Establish flexible arrangements for recruitment of researchers and candidates to our PhD-programme for future academic positions and provide academic skills into clinical medicine
  • Provide arenas for scientific discussions, structured tutoring, and training in scientific communication in order to achieve efficient and successful PhD-candidates


Page administrator: Helle Jørgensen
created: 06.06.2014 14:15
Skip to main content